
Development and production of active pharmaceutical ingredients (APIs) and highly active pharmaceutical ingredients (HAPIs) for cancer treatments.
B
CSR Analysis score
The organization is among the top 20% of most committed organizations, excluding the top 5%, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: March 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
EUROAPI
B
Production and distribution of active pharmaceutical ingredients (APIs) for healthcare professionals.
Seqens
A
Manufacturing of a broad range of ingredients for the pharmaceutical industry, including generic and custom APIs, intermediates, and excipients.
ProteoGenix
B
Development and production of therapeutic antibodies, protein expression, peptide synthesis, gene synthesis, bioproduction, bioanalytics, and custom assay development for the biopharmaceutical industry.
Initiatives identified among leaders
Réduction de l'empreinte carbone et environnementale
“Seqens lance le projet Phoenix pour produire du pa...” - SeqensPromesse, engagement public
“EUROAPI s'engage à atteindre des objectifs environ...” - EUROAPITransition vers des énergies renouvelables
“Seqens s'engage à réduire son empreinte carbone en...” - Seqens64% of similar organizations communicate on CSR issues
+3195 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports